low - Vaccine demand driven by epidemiology and public health policy rather than GDP. However, discretionary vaccine uptake (non-mandated boosters) shows modest correlation to consumer confidence. Government budget constraints during recessions could impact pandemic preparedness funding and advance purchase agreements. Commercial insurance reimbursement stable regardless of cycle.

High sensitivity through valuation multiple compression rather than operations. As unprofitable growth biotech with $9.5B cash and minimal debt (0.15 D/E), rising rates increase discount rate applied to out-year pipeline value (2028-2030+ revenue potential). 10-year Treasury moves directly impact biotech sector multiples. Operationally, interest income on cash balances provides modest offset ($300-400M annually at current rates). No meaningful financing cost exposure given strong balance sheet.

growth/speculative - Attracts biotech specialists betting on platform value and pipeline optionality despite current unprofitability. High-risk/high-reward profile with binary clinical trial outcomes. Momentum traders active given 69% 3-month return on pipeline optimism. Value investors largely absent given negative earnings and 8.5x P/S on declining revenue base. Not suitable for income investors (no dividend, cash burn).